IARC HANDBOOKS



CERVICAL CANCER SCREENING

VOLUME 18

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met remotely, 12–16 October 2020

LYON, FRANCE - 2022

IARC HANDBOOKS OF CANCER PREVENTION

International Agency for Research on Cancer

World Health Organization

Fig. S1 PRISMA flow diagram showing the retrieval and selection of studies



A, no primary data (letter, comment, review, economical study, protocol); B, double reporting; C, irrelevant population (triage not of HPV-positive women, or of HPV-positive women but not from screening); D, no triage testing; E, no comparative data (triage other than cytology or VIA); F, no accuracy data for detection of CIN2+ or CIN3+; G, long time interval between tests; H, triage test not defined or not applicable, or hierarchical categorization of extended genotyping; I, key data not extractable.
CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; HPV, human papillomavirus; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; VIA, visual inspection with acetic acid.
Created by the Working Group.